simeprevir (Olysio, TMC435)
Jump to navigation
Jump to search
Indications
- for use with pegylated interferon & ribovirin for treatment of hepatitis C virus genotype 1 in adults[1][2]
* potential to be repurposed as COVID-19 therapy[5]
Dosage
- 150 mg PO daily
Capsule: 150 mg
Adverse effects
- may exacerbate hepatitis B infection[3][4]
Mechanism of action
- NS3/4A antiviral protease inhibitor
More general terms
References
- ↑ 1.0 1.1 Sax PE HIV and ID Observations Simeprevir and Sofosbuvir Submitted to FDA - Clock Ticking on Boceprevir, Telaprevir, Even Interferon cited in: Physician's First Watch for April 11, 2013 Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org http://blogs.jwatch.org/hiv-id-observations/index.php/simeprevir-and-sofosbuvir-submitted-to-fda-clock-ticking-on-boceprevir-telaprevir-even-interferon/2013/04/10/?q=pfw-featured
- ↑ 2.0 2.1 FDA News Release: Nov. 22, 2013 FDA approves new treatment for hepatitis C virus http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376449.htm
- ↑ 3.0 3.1 Collins JM et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis 2015 Oct 15; 61:1304. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26082511 <Internet> http://cid.oxfordjournals.org/content/61/8/1304
Balagopal A and Thio CL. Another call to cure hepatitis B. Clin Infect Dis 2015 Oct 15; 61:1307 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26082512 <Internet> http://cid.oxfordjournals.org/content/61/8/1307 - ↑ 4.0 4.1 FDA Drug Safety Communication: Oct 4, 2016 FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. http://www.fda.gov/Drugs/DrugSafety/ucm522932.htm
- ↑ 5.0 5.1 The Scripps Research Institute Extensive study identifies over a dozen existing drugs as potential COVID-19 therapies. MedicalXpress 2021. June 3 https://medicalxpress.com/news/2021-06-extensive-dozen-drugs-potential-covid-.html